Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ayala Pharmaceuticals Inc
(OP:
ADXS
)
0.0270
UNCHANGED
Streaming Delayed Price
Updated: 1:07 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ayala Pharmaceuticals Inc
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
May 09, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
March 26, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
November 06, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
October 23, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
October 19, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
August 01, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
July 27, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
July 05, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 05, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 23, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2023
Poster will feature updated results from Phase 2 portion of RINGSIDE, evaluating AL102 in desmoid tumors
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
March 03, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
February 10, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
October 19, 2022
From
Ayala Pharmaceuticals
Via
GlobeNewswire
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS
March 28, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
INVESTIGATION: Halper Sadeh LLP Investigates LONE, KIN, GRA, ADXS; Shareholders are Encouraged to Contact the Firm
July 22, 2021
NEW YORK, NY / ACCESSWIRE / July 22, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Lonestar Resources US Inc. (OTCQX:LONE)...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
INVESTIGATION ALERT: Halper Sadeh LLP Investigates JAX, STMP, IKNX, ADXS; Shareholders are Encouraged to Contact the Firm
July 11, 2021
NEW YORK, NY / ACCESSWIRE / July 11, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: J. Alexander's Holdings, Inc. (NYSE:JAX)...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
INVESTIGATION ALERT: Halper Sadeh LLP Investigates CORE, CAI, BOCH, ADXS; Shareholders are Encouraged to Contact the Firm
July 10, 2021
NEW YORK, NY / ACCESSWIRE / July 10, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Core-Mark Holding Company, Inc....
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
ADVAXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Advaxis, Inc. - ADXS
July 07, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.